HUP0200803A3 - Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates - Google Patents

Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates

Info

Publication number
HUP0200803A3
HUP0200803A3 HU0200803A HUP0200803A HUP0200803A3 HU P0200803 A3 HUP0200803 A3 HU P0200803A3 HU 0200803 A HU0200803 A HU 0200803A HU P0200803 A HUP0200803 A HU P0200803A HU P0200803 A3 HUP0200803 A3 HU P0200803A3
Authority
HU
Hungary
Prior art keywords
intermediates
pharmaceutical compositions
compositions containing
bicyclic heteroaryl
substituted bicyclic
Prior art date
Application number
HU0200803A
Other languages
English (en)
Original Assignee
Aventis Pharma Ltd West Mallin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908355.2A external-priority patent/GB9908355D0/en
Application filed by Aventis Pharma Ltd West Mallin filed Critical Aventis Pharma Ltd West Mallin
Publication of HUP0200803A2 publication Critical patent/HUP0200803A2/hu
Publication of HUP0200803A3 publication Critical patent/HUP0200803A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HU0200803A 1999-04-12 2000-04-12 Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates HUP0200803A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908355.2A GB9908355D0 (en) 1999-04-12 1999-04-12 Chemical compounds
US14147099P 1999-06-29 1999-06-29

Publications (2)

Publication Number Publication Date
HUP0200803A2 HUP0200803A2 (hu) 2002-07-29
HUP0200803A3 true HUP0200803A3 (en) 2002-12-28

Family

ID=26315408

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200803A HUP0200803A3 (en) 1999-04-12 2000-04-12 Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates

Country Status (24)

Country Link
US (1) US6706738B2 (hu)
EP (1) EP1183254B1 (hu)
KR (1) KR20010110750A (hu)
CN (1) CN1350534A (hu)
AT (1) ATE286896T1 (hu)
AU (1) AU769554B2 (hu)
BG (1) BG106083A (hu)
BR (1) BR0010599A (hu)
CA (1) CA2369728A1 (hu)
CZ (1) CZ20013661A3 (hu)
DE (1) DE60017389T2 (hu)
EE (1) EE200100528A (hu)
ES (1) ES2231179T3 (hu)
HK (1) HK1044937A1 (hu)
HR (1) HRP20010732A2 (hu)
HU (1) HUP0200803A3 (hu)
IL (2) IL145748A0 (hu)
MX (1) MXPA01010231A (hu)
NO (1) NO20014951L (hu)
NZ (1) NZ514602A (hu)
PL (1) PL351433A1 (hu)
SK (1) SK14372001A3 (hu)
TR (1) TR200102959T2 (hu)
WO (1) WO2000061580A1 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2290403C2 (ru) 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Ингибиторы vla-4
WO2003082272A1 (en) * 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
CA2553423C (en) 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
BRPI0514379A (pt) * 2004-08-16 2008-06-10 Procter & Gamble compostos de 2-(amino ou amino substituìdo) fenol-5, 6-substituìdo, composições para tingimento contendo os mesmos, e uso das mesmas
DE102004041137A1 (de) * 2004-08-25 2006-03-02 Wella Ag o-Aminophenol-Derivate und diese Verbindungen enthaltende Färbemittel
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US7931838B2 (en) * 2006-08-31 2011-04-26 Virginia Tech Intellectual Properties, Inc. Method for making oriented single-walled carbon nanotube/polymer nano-composite membranes
JP5343082B2 (ja) * 2007-10-29 2013-11-13 アムジエン・インコーポレーテツド ベンゾモルホリン誘導体および使用方法
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
AU2014232954B2 (en) 2013-03-15 2018-08-09 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
KR102787208B1 (ko) * 2014-05-16 2025-03-27 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 티오에테르 펩티드 길항제
BR112017001010A2 (pt) 2014-07-17 2017-11-14 Protagonist Therapeutics Inc inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais
BR112017006826A2 (pt) 2014-10-01 2017-12-12 Protagonist Therapeutics Inc novos monômeros e dímeros peptídicos a4ss7 antagonistas
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
TW202515892A (zh) 2020-01-15 2025-04-16 美商健生生物科技公司 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3202226A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
TWI247008B (en) * 1998-04-10 2006-01-11 Searle & Co Heterocyclic glycyl beta-alanine derivatives
ATE325105T1 (de) * 1999-02-16 2006-06-15 Aventis Pharma Ltd Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden

Also Published As

Publication number Publication date
NZ514602A (en) 2003-06-30
ES2231179T3 (es) 2005-05-16
TR200102959T2 (tr) 2002-04-22
BG106083A (en) 2002-05-31
AU769554B2 (en) 2004-01-29
CA2369728A1 (en) 2000-10-19
NO20014951D0 (no) 2001-10-11
PL351433A1 (en) 2003-04-22
CZ20013661A3 (cs) 2002-01-16
WO2000061580A1 (en) 2000-10-19
HK1044937A1 (zh) 2002-11-08
EP1183254A1 (en) 2002-03-06
US6706738B2 (en) 2004-03-16
ATE286896T1 (de) 2005-01-15
EP1183254B1 (en) 2005-01-12
IL145748A0 (en) 2002-07-25
IL145748A (en) 2007-02-11
SK14372001A3 (sk) 2002-06-04
KR20010110750A (ko) 2001-12-13
MXPA01010231A (es) 2003-07-21
NO20014951L (no) 2001-12-11
US20020173506A1 (en) 2002-11-21
BR0010599A (pt) 2002-02-13
DE60017389D1 (de) 2005-02-17
HRP20010732A2 (en) 2002-12-31
HUP0200803A2 (hu) 2002-07-29
AU3981600A (en) 2000-11-14
DE60017389T2 (de) 2006-03-02
CN1350534A (zh) 2002-05-22
EE200100528A (et) 2003-02-17

Similar Documents

Publication Publication Date Title
HUP0200803A3 (en) Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates
HUP0200653A3 (en) Bicyclic heteroaromatic compounds useful as lh agonists, pharmaceutical compositions containing them and their use
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HUP0201900A3 (en) Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0600592A2 (en) Substituted imidazopyridines, pharmaceutical compositions containing them and intermediates
HUP0204413A3 (en) Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0400058A2 (hu) Kondenzált heterogyűrűs vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
HUP0301654A3 (en) Novel n-pyrimidinyl-sulfamides, their use as endothelin receptor antagonists and pharmaceutical compositions containing them
HUP0203766A3 (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them
HUP0303103A3 (en) Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds
PL350522A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
IL145013A0 (en) Tricyclic compounds, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0500107A3 (en) 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
IL168784A (en) Fused 1,3-dihydroimidazole ring compounds and pharmaceutical compositions comprising the same
IL156939A0 (en) Urea derivatives as integrin alpha 4 antagonists
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
HUP0202520A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
HUP0203108A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
IL146104A0 (en) Substituted bicyclic heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing the same
HUP0200281A2 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0204006A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees